Methamphetamine Use Disorder
37
12
17
12
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.1%
3 terminated out of 37 trials
80.0%
-6.5% vs benchmark
3%
1 trials in Phase 3/4
58%
7 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (37)
Methamphetamine and Troriluzole
Non-Abstinence Outcomes in Methamphetamine Use Disorder
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
Methamphetamine Use Disorder Support in Heart Failure Pilot Study
LDART for Stimulant Use Disorder
Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii
ECG Findings in Methamphetamine Use
A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder
LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
α-N-acetylgalactosaminidase in Methamphetamine Psychosis
Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder
Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia
Paired-pulse rTMS Treatment for Methamphetamine Use Disorder Based on the mPFC-Cerebellum
Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization
Beginning Early and Assertive Treatment for Methamphetamine Use Disorder
Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM
Psilocybin for Methamphetamine Addiction
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder